News | January 01, 2026
Establishment Labs seeks FDA nod for Motiva breast reconstruction implants
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
Theracor is derived from human umbilical cord extracellular matrix (ECM) and is designed to cover, protect, and maintain a moist wound environment
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
Applications include detailed scientific rationale and supporting clinical evidence
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Subscribe To Our Newsletter & Stay Updated
